Structural basis for nucleotide exchange on G i subunits and receptor coupling specificity by Johnston, Christopher A. & Siderovski, David P.
Structural basis for nucleotide exchange on Gi
subunits and receptor coupling specificity
Christopher A. Johnston and David P. Siderovski*
Department of Pharmacology and UNC Neuroscience Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7365
Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved December 19, 2006 (received for review September 28, 2006)
Heterotrimeric G proteins are molecular switches that relay infor-
mation intracellularly in response to various extracellular signals.
How ligand-activated G protein-coupled receptors act at a distance
to exert exchange activity on the G nucleotide binding pocket is
poorly understood. Here we describe the synergistic action of two
peptides: one from the third intracellular loop of the D2 dopamine
receptor (D2N), and a second, GGDP-binding peptide (KB-752)
that mimics the proposed role of G in receptor-promoted nu-
cleotide exchange. The structure of both peptides in complex with
Gi1 suggests that conformational changes in the 3/2 loop and
6 strand act in concert for efficient nucleotide exchange. Two key
residues in the 4 helix were found to define a receptor/Gi
coupling specificity determinant.
G protein-coupled receptors  guanine nucleotide exchange 
heterotrimeric G proteins
G protein-coupled receptors (GPCRs) activate heterotri-meric G proteins by catalyzing the exchange of GDP for
GTP on the G subunit, thus initiating signaling to cellular
enzymes and ion channels (1). However, the mechanism by
which GPCRs stimulate guanine nucleotide exchange on het-
erotrimeric G proteins remains poorly understood. Crystal struc-
tures of the prototypical GPCR, rhodopsin (2, 3), have provided
the first structural glimpse of a G-directed guanine nucleotide
exchange factor (GEF). However, the rhodopsin structures do
not include bound heterotrimer and thus afford limited direct
information regarding the mechanism of GPCR-mediated G
protein activation.
One unifying aspect of several current models of GPCR GEF
activity (4–6) is that ligand-activated receptor must act at a
distance to transmit conformational changes through distinct
regions of the G protein, because the GDP-binding pocket of G
resides 30 Å away from the receptor, precluding the possibility
of direct manipulation of this region in its proposed orientation
at the receptor interface (7, 8). One proposed model suggests
that the receptor uses G as a ‘‘lever’’ to reorient the 3/2 loop
of G (5). The 3/2 loop in this model serves as an occlusive
barrier to GDP release, and receptor-promoted alterations in its
conformation (i.e., removal from the GDP-binding pocket)
thereby create a feasible egress route for GDP. An alternative
hypothesis suggests that receptors use the extreme C terminus of
G as a ‘‘latch’’ to alter the conformation of the 5 helix (6, 9,
10). Modulation of the 5 helix, in turn, is suggested to alter the
6/5 loop conformation and destabilize contacts with the
guanine ring of GDP, thus allowing for nucleotide release. We
recently reported the structure of Gi1 bound to a G-
surrogate peptide, KB-752, which acts as a G GEF by displacing
the occlusive 3/2 lip in an analogous manner to that proposed
for receptor-mediated tilting of G during activation (5, 11).
Because these studies with KB-752 were illustrative only of the
G contribution to heterotrimer activation by activated recep-
tor, here we investigated the effects of KB-752 on G in
combination with a receptor fragment that also possesses GEF
activity. We have determined the structure of a complex of these
two GEF peptides bound to Gi1, a structure that has revealed
critical determinants for receptor/G coupling and receptor-
mediated nucleotide exchange.
Results and Discussion
Nanoff et al. (9) recently described a peptide with GEF activity,
D2N, derived from the N-terminal region of the third intracel-
lular (ic3) loop of the D2-dopamine receptor. D2N and several
other receptor-derived peptides have been shown to elicit mod-
est exchange factor activity in vitro toward specific G subunits
and are therefore thought to represent direct receptor/G
engagement sites acted on during GPCR-mediated activation
(12). When used alone (at maximally effective concentrations;
see refs 9 and 11), KB-752 and D2N each stimulated the rate of
GTPS binding (Fig. 1A Inset). Notably, combining KB-752 and
D2N resulted in a rate of GTPS binding approaching that of a
full-length receptor acting on the G heterotrimer in recon-
stituted systems and cell membrane preparations (13). Peptide
effects were predominantly seen in the initial reaction rate;
modest effects on the overall magnitude of GTPS binding to
Gi1 likely reflect the ability of these peptides to reduce the
requirement on magnesium for GTPS binding similar to that
displayed by activated receptors (9, 14). To investigate these
peptide effects more fully, we focused on initial GTPS binding
rates under each condition. When combined, KB-752 and D2N
resulted in a synergistic enhancement of the initial GTPS
binding rate (Fig. 1 A). We also assessed the effects of each
peptide under steady-state GTP hydrolysis conditions in which
nucleotide exchange is rate-limiting (15). Similar to GTPS
binding, both KB-752 and D2N modestly enhanced steady-state
GTP hydrolysis; however, their combined effect was again
synergistic. These results suggest that KB-752 and D2N impart
GEF activity by distinct mechanisms and that robust exchange by
G is achieved through a multiple-site mechanism.
To examine the synergistic actions of KB-752 and D2N in more
detail, we carried out dose–response analyses of each peptide in
the absence and presence of a constant concentration of its
synergistic partner. In both cases tested, no effect was observed
on the potency of either peptide: the presence of D2N does not
significantly affect the potency of KB-752 (Fig. 1C), and the
presence of KB-752 does not significantly affect the potency of
D2N (Fig. 1D). These results suggest that no allosteric interac-
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tion occurs between the binding sites of KB-752 and D2N to alter
the ability of either peptide to interact with G; instead, these
results suggest that simultaneous binding of peptides impinge on
separate structural elements within G to elicit efficient nucle-
otide exchange. Although the structural elements engaging
KB-752 and D2N can cooperatively regulate the release of GDP,
our data suggest that these elements themselves are not ther-
modynamically coupled.
To ascertain the structural determinants of this synergistic
exchange activity and its potential relationship to receptor-
promoted exchange, we determined the crystal structure of Gi1
bound to both D2N and KB-752 peptides. Diffraction data
collected from a single crystal at 100 K were used to refine a
model of the structure to 2.2-Å resolution (see supporting
information (SI) Table 1) by using the structure of
Gi1GDPMg2 as a model for molecular replacement (16).
KB-752 is bound in a conserved hydrophobic cleft created by the
2 (switch II) and 3 helices (Fig. 2A) in a nearly identical
fashion as the previously determined Gi1/KB-752 dimer struc-
ture (11). All major contacts made between KB-752 and Gi1 in
the Gi1/KB-752 dimer are conserved in the D2N/Gi1/KB-752
structure, with an additional contact observed between Lys-257
in the 3/5 loop of Gi1 and glutamate-11 in KB-752 (data not
shown). The binding of KB-752 is seen to displace switch II,
along with the 3/2 loop, away from the GDP-binding pocket
(Fig. 2 A) relative to their positions in either peptide-unbound
Gi1 or Gi112 structures, a similar displacement to that seen
in Gi1/KB-752 (11).
Electron density suitable for model building (e.g., SI Fig. 5)
was observed for a short basic cluster of D2N (11RRRK14;
corresponding to 216RRRK219 in the human D2-dopamine re-
ceptor), a region predicted to comprise the extreme N-terminal
region of the ic3 loop (17). The D2N peptide binds in the 4/6
region on the opposite face of G relative to the KB-752 binding
site (Fig. 2 A and B). This region has been described as a critical
rhodopsin/transducin contact site, although the interaction site
on rhodopsin was not delineated (18). The 4/6 loop has an
electronegative, acidic potential that complements the elec-
tropositive, basic cluster of D2N (Fig. 3 A and B). D2N engages
a triad of residues on the 4 helix and 6 strand (Q304/E308 and
T321, respectively; Fig. 2B) that were implicated in studies using
G chimera (19–21) in the coupling specificity and GEF activity
of the 5-HT1A serotonin receptor. Binding of D2N results in
displacement of the Gi1 6 strand with respect to the unbound
state (Fig. 2C) and the KB-752-bound state (Fig. 2D), along with
an alteration in the 4/6 loop. This displacement in the 6
strand, albeit minor, positions T321 farther away from residues
Q304 and E308 of the 4 helix, likely weakening their interac-
tions. The disposition of the 6 strand is unaltered between
unbound and KB-752-bound Gi1 [Protein Data Bank (PDB) ID
codes 1AS3 and 1Y3A, respectively; SI Fig. 6], suggesting that
KB-752 binding does not alter the conformation of the D2N-
binding site significantly from the unbound state. This result
supports the biochemical data above that KB-752 does not alter
the potency of D2N-mediated exchange factor activity (Fig. 1D).
The 6/5 loop makes contacts with the guanine ring of GDP
(Fig. 2B) and is thought to stabilize its binding to G; mutations
in this region lead to enhanced spontaneous GDP release (22,
23). Thus, receptor-mediated modulation of the 6/5 loop
through displacement of the 6 strand may relieve these stabi-
lizing contacts with GDP resulting in enhanced nucleotide
exchange. The lack of observable conformational changes within
the 6/5 loop per se (Fig. 2 C and D) likely results from the
inability to isolate the GDP-free form of G and suggests that
our structural model reflects an exchange reaction intermediate
stabilized within the crystal lattice. Previous studies have sug-
gested that receptor coupling to the extreme C terminus of G
may serve to induce a conformational change in the 5 helix that
could, in turn, alter the disposition of the 6/5 loop (6, 18). Our
structural data now highlight a similar role for a receptor-
mediated conformational change in the 6 strand also predicted
to translate into an alteration of the 6/5 loop (Fig. 2C). We
hypothesize that the receptor uses multiple contact sites to
simultaneously alter the 6 strand and 5 helix to ultimately
A C
B D
Fig. 1. Synergistic effects of peptide GEFs on Gi1. (A) 30 M KB-752 or 3 M D2N each effect a weak stimulation of [35S]GTPS binding over 2 min by 50 nM
Gi1 protein (1.7- and 3.5-fold, respectively); however, combining the two peptides at these same concentrations yields a nonadditive 15.7-fold stimulation.
(Inset) Representative kinetic analysis of [35S]GTPS binding under indicated conditions. (B) 100 M KB-752 or 3 M D2N alone also weakly stimulate steady-state
GTP hydrolysis by 100 nM recombinant Gi1 protein (3.6- and 4.5-fold, respectively); however, addition of both peptides again results in a nonadditive 18.8-fold
stimulation. Note that the rate-limiting step for steady-state GTP hydrolysis by G subunits is product (GDP) release (15). (C) Addition of 3 M D2N does not alter
the potency of KB-752-stimulated [35S]GTPS binding. (D) Similarly, addition of 30 M KB-752 does not alter the potency of D2N-stimulated [35S]GTPS binding
[the biphasic dose-response characteristic of D2N has been noted to occur previously (9)].
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impinge on critical contacts between the 6/5 loop and GDP.
However, the synergistic activity between D2N and KB-752
suggests that modulation of the 6/5 loop alone is insufficient
for maximal GEF activity and that the 3/2 loop serves as a
second determinant of GDP release. The receptor thus would
use direct contacts with the 6 strand and/or 5 helix to release
guanine base contacts with the 6/5 loop, coincident with
G-mediated levering of the 3/2 loop to remove the occlu-
sive lip blocking GDP release, to invoke maximally efficient
nucleotide release.
Our results demonstrating D2N bound in the 4/6 loop of
Gi1 contrasts with a previous report suggesting that the D2N-
binding site resides in the 5 helix and/or extreme C terminus of
G (9). This suggestion was based largely on the ability of a C
terminus-directed G antibody to neutralize the exchange factor
activity of D2N; however, the possibility exists that the antibody
perturbed D2N effects through steric interactions with an alter-
native binding site (namely, the 4/6 loop). The close proximity
of the 5 helix and C terminus to the 4/6 loop (see Fig. 2 A)
suggests such a possibility. Also, mutation of an 5 helix residue
(I343P), designed to reduce its f lexibility, reduced the efficacy of
D2N toward Gi1 (9). However, the effects of the I343P muta-
tion were incomplete and suggest that the integrity of the 5
helix needs to be maintained for full D2N responsiveness.
Interestingly, the results of Nanoff et al. (9), together with our
findings of 6 strand modulation upon D2N binding, suggest a
link between the 6 strand and 5 helix, perhaps resulting in
cooperative effects on displacing the 6/5 loop.
To validate our structural model, we generated a 216RRRK219 to
216AAAA219 mutation in the human D2L-dopamine receptor and
examined agonist-promoted [35S]GTPS binding to G in mem-
branes from COS-7 cells expressing these receptor constructs.
Radioligand binding assays indicated that both wild-type (WT) and
mutant receptors were capable of binding the D2-receptor antag-
onist [3H]spiperone with identical affinity and efficacy (Fig. 3C
Inset), suggesting that the 216AAAA219 mutation does not alter
cell-surface trafficking or ligand-binding properties of the receptor.
Whereas the D2-selective agonist, quinpirole, enhanced
[35S]GTPS binding in membranes expressing WT receptor (Fig.
3C), no agonist effect was seen in membranes expressing the
mutated receptor. The D2-selective antagonist spiperone com-
pletely abolished the quinpirole-mediated stimulation, indicating a
receptor-specific effect (Fig. 3C). The loss of agonist activation in
the 216AAAA219 mutated D2-receptor underscores a critical role
for this basic cluster in the N-terminal ic3 region for agonist-
mediated activation of G; these results are also supported by
previous studies of the related D4-dopamine receptor implicating
the corresponding region in its G protein coupling and activation
capabilities (24). Furthermore, these results support a role for
charge–charge complementation in receptor/G coupling (Fig. 3 A
and B) as postulated for other GPCRs, including rhodopsin and the
5-HT1A serotonin receptor (20).
We next investigated the role of the 216RRRK219 basic cluster
on G protein-mediated signaling in intact cells. Gi/o-coupled
receptors, including D2-dopamine receptors, activate phospho-
lipase-C (PLC)  isozymes through the release of G subunits
(25). WT D2 receptors were capable of stimulating inositol
phosphate production in COS-7 cells coexpressing PLC-2 in an
agonist-dependent manner (Fig. 3D). In contrast, cells express-
ing the 216AAAA219 mutant D2 receptor failed to elicit any
response (Fig. 3D). Expression levels of WT and mutant D2
receptors, as well as PLC-2, were not significantly different
between conditions (Fig. 3D inset). These data suggest that the
216RRRK219 sequence in the D2-dopamine receptor indeed
contributes directly to G protein coupling and activation in a
cellular environment.
Dopamine receptors are classified into two major subfamilies:
the D1-like family (D1 and D5 receptors) and the D2-like family
(D2, D3, and D4 receptors) that selectively couple to Gs and
Gi/o subunits, respectively (25). Previous studies with the D2N
peptide have demonstrated selective GEF activity on Gi/o
subunits over Gs, suggesting that this region of the D2 receptor
aids in G protein coupling specificity (9). Moreover, peptides
derived from an analogous region of the D1-receptor ic3 loop fail
to activate Gi subunits (26). Thus, the Gi1/D2N interface likely
represents a structural glimpse of a bona fide receptor/G
interaction. Notably, the 4 helix residues Q304 and E308
contacted directly by D2N basic residues (Fig. 2B) have been
implicated in the G protein coupling specificity of the 5-HT1A
serotonin receptor (21). Mutation of these two 4 helix residues
within Gi1 to the corresponding residues in Gs (Q304R/
E208L; Fig. 4A), which does not couple to D2-like receptors,
abrogated D2N-mediated exchange activity (Fig. 4B). Con-
versely, whereas WT Gs was unaffected by D2N (as described
in ref. 9), mutation of 4 helix residues in Gs to the corre-
sponding Gi1 sequence (R342Q/L346E; Fig. 4A) imparted D2N
sensitivity to Gs (Fig. 4B). Similar specificity switching was
observed for the GEF activities of two additional, D2N-like
Fig. 2. Structural model of the D2N/Gi1/KB-752 trimer. (A) Overall structure
of D2N/Gi1/KB-752 illustrating the locations of the Ras-like domain (blue),
all-helical domain (yellow), switches I-III (green), KB-752 (red), and D2N
(orange). KB-752 binds between the 2 (switch II) and 3 helices of G and,
compared with unbound Gi1, displaces the 2 helix and 3/2 loop away from
the GDP-binding pocket. D2N binds on the opposite face of Gi1 near the
4/6 loop. (B) View of the Gi1/D2N interface showing critical contacts. The
basic 11RRRK14 sequence within D2N binds an acidic patch in the 4/6 loop
(see also Fig. 3 A and B). Contacts (4 Å) are illustrated by dashed lines with
Gi1 and D2N residues labeled in blue and orange, respectively. (C) Superpo-
sition of unbound Gi1 (gray-to-black; PDB ID code 1AS3) and KB-752/D2N-
bound (orange) Gi1 reveals a reorientation (1.51 Å rmsd) of the 4/6 loop
and 6 strand leading into the 6/5 loop that makes contacts with the
guanine ring of GDP (magenta). The magnitude of the 4/6 loop and 6
strand reorientation is greater than that of the overall rmsd of the G
superposition (0.45 Å) as well as more than double that of the 5 helices
between the two structures (0.57 Å). (D) Superposition of KB-752-bound Gi1
(blue; PDB ID code 1Y3A) and KB-752/D2N-bound Gi1 (orange) demonstrates
that a similar shift of the 6 strand is seen in the dual peptide-bound state
compared with the KB-752-bound structure, suggesting this conformational
change in the 6 strand likely governs D2N action.









peptides derived from the ic3 loops of Gi/o-coupled 5-HT1A
serotonin and 2B adrenergic receptors (Fig. 4 C and D). In
addition, Go, which couples to D2 receptors (25) and is also a
D2N substrate (9), has residues Q304 and E308 in its 4 helix like
Gi1 (Fig. 4A). In fact, all members of the Gi family have
glutamine and glutamate residues conserved at these two posi-
tions, whereas all other G subunits are highly divergent,
typically displaying either basic or aliphatic residues at one or
both positions (Fig. 4A). Collectively, these sequence conserva-
tion and biochemical results strongly suggest that, although other
receptor/G protein contacts most likely also contribute to the
interaction (e.g., see ref. 7 for a review concerning G C
terminus contributions), the D2-dopamine receptor, and possi-
bly other related GPCRs like 5HT1A-R and 2B-AR, use the
N-terminal region of the ic3 loop to bind Q304/E308 in the 4
helix of Gi1 to impart coupling specificity.
Although others have used NMR to gain structural information
regarding isolated receptor loop peptides (e.g., refs 27 and 28), to
our knowledge, a crystal structure illuminating the process of
GPCR-promoted GEF activity has not been reported previously.
The structural model of Gi1 bound simultaneously to the two GEF
peptides KB-752 and D2N highlights specific molecular determi-
nants of receptor/G protein coupling and a proposed mechanism of
receptor-catalyzed nucleotide exchange involving synergistic con-
tributions of 3/2 occlusive lip removal by G and 6/5 loop
modulation by the ic3 loop of the receptor. In agreement with this
notion, recent studies using electron paramagnetic resonance
(EPR) have demonstrated that light-activated rhodopsin catalyzes
structural changes in residues within the 5 helix and 6 strand (29)
as well as the 3/2 loop and switch II helix (10) of G during
nucleotide exchange. Collectively, this structural information sheds
new light on how these clinically important receptors communicate
ligand binding into heterotrimeric G protein activation critical to
cellular physiologic responses and to therapeutics targeted to
manipulate them.
Materials and Methods
Expression and Purification. Bacterial purification of full-length
human Gi1 was conducted as described (30). Peptides D2N
(VYIKIYIVLRRRRKRVNTK; refs. 9 and 26), KB-752 (SRVT-
WYDFLMEDTKSR; ref. 11), and all other peptides used were
synthesized by Fmoc-group protection and purified through
HPLC by the Tufts University Core Facility (Medford, MA).
Cell Culture and Transfection. COS-7 cells were maintained in
DMEM with 10% FBS and penicillin/streptomycin. Hemagglu-
tinin-epitope (HA)-tagged D2L-dopamine receptor cDNA was
obtained from the UMR cDNA Repository (www.cdna.org) and
Fig. 3. Modeling and validation of the electrostatic complementarity underlying the G/D2-receptor coupling interaction. (A and B) Plotting of the electrostatic
potentials of a D2-dopamine receptor homology model (A; ref. 17) and the Gi112 heterotrimer (B; PDB ID code 1GP2) reveals specific charge complementation
supportive of the basic D2N cluster engaging the acidic 4/6 region of Gi1. (A) The receptor is displayed as the ‘‘intracellular face’’ (i.e., as if looking toward
the plasma membrane); relative locations of the highly conserved DRY peptide triad critical for receptor activation (39), the ic1 and ic2 loops, and the receptor
C terminus are also outlined with ovals. (B) The heterotrimer is displayed as the ‘‘top face’’ proposed to orient to the receptor (i.e., as if looking downward from
the plasma membrane); relative locations of the 4/6 region, GDP-binding site, and G N and C termini are outlined with ovals. (C and D) Alanine mutation
of the basic cluster 216RRRK219 in the full-length D2L-dopamine receptor abrogates agonist-stimulated GTPS binding (C) and effector stimulatory (D) activities.
(C) Cells were transiently transfected with empty vector control, WT, or alanine-mutated (AAAA) D2L-receptor and plasma membranes isolated and assessed for
10 M quinpirole-stimulated [35S]GTPS binding. The D2-selective antagonist, spiperone, completely abolished the agonist-mediated response by WT receptor.
(Inset) Receptor-binding analysis with [3H]spiperone revealed that the alanine mutant receptor retains ligand-binding properties indistinguishable from WT
receptor. (D) Cells were transfected with PLC-2 in combination with either WT or alanine-mutated receptor, and accumulation of [3H]inositol phosphates (IPx)
was measured. Quinpirole elicited a statistically significant 2-fold increase in [3H]IPx from WT receptor, a response that was blocked by spiperone; however,
quinpirole had no discernable effect on the alanine-mutated receptor. (*, P  0.05; one-way ANOVA followed by Bonferroni posthoc multiple comparison
analysis). (Inset) Western blot analysis shows an equal expression of D2L-receptor expression (detected by an N-terminal HA tag) and PLC-2 under each cellular
cotransfection condition: lane 1, empty vectors; lane 2, empty vector  PLC2; lane 3, WT receptor  PLC2; lane 4, alanine mutant receptor  PLC2.
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mutated by using standard protocols (Quickchange; Stratagene,
La Jolla, CA). For receptor-promoted [35S]GTPS exchange
assays, 10-cm2 dishes with cells 50–60% confluent were trans-
fected with 10 g of desired receptor construct (or pcDNA3.1
plasmid control) combined with 30 l of Fugene-6 (Roche,
Indianapolis, IN). After 48 h, cells were harvested and plasma
membranes were isolated as described (31).
Biochemical Assays. [35S]GTPS binding assays were performed
essentially as described (9) by using assay buffer containing 2 mM
free Mg2. G proteins were incubated at room temperature with
peptides for 5 min before reaction initiation. Reactions were
incubated at either 30°C (Gi1 and Gi/t) or 20°C (Gs). Experi-
ments using D2-receptor expressing COS-7 membranes were incu-
bated for 60 min at 22°C. Steady-state GTP hydrolysis assays were
carried out as described (32). Reactions were otherwise carried out
under conditions identical to [35S]GTPS binding assays.
Inositol Phosphate Accumulation. COS-7 cells were grown in 12-
well culture dishes and transfected with human PLC-2 and D2
receptor constructs in a 3:1 ratio (total 400 ng DNA plus 1.2 l
Fugene per well). After 24 h, cells were treated with [3H]inositol
(1 Ci per well) and incubated overnight. Cells were then
treated with D2 receptor ligands in the presence of LiCl (5 M).
Accumulation of [3H]inositol phosphates was subsequently an-
alyzed as described (33).
Crystallization and Structural Determination. Crystals of D2N and
KB-752 peptides bound to Gi1 were obtained by vapor diffusion
from hanging drops containing a 1:1 (vol/vol) ratio of protein/
peptide solution (15 mgml1 Gi1, 1.5 molar excess D2N, and 1.5
molar excess KB-752 in 50 mM Hepes, pH 8.0/1 mM EDTA/10
M GDP/5 mM DTT) to well solution (2.05 M ammonium
sulfite/100 mM sodium acetate, pH 6.0). Crystals (0.6  0.2 
0.1 mm) formed in 3–5 days at 20°C in the space group I4 (a 
b  120.4 Å, c  69.8 Å,       90°), with one
D2N/Gi1/KB-752 heterotrimer in the asymmetric unit. For data
collection at 100 K, crystals were transferred to well solution
supplemented with 20% glycerol for 30 sec followed by im-
mersion in liquid nitrogen. A native data set was collected on a
single crystal by using an R-Axis IV detector with rotating
anode generator (Rigaku, The Woodlands, TX) and osmic
confocal ‘‘blue’’ optics. Diffraction data were scaled and indexed
by using HKL2000 (34). The structure of Gi1GDP (PDB ID
code 1AS3), excluding GDP, waters, and other heterogeneous
(nonpeptide) molecules, was used as a molecular replacement
model for D2N/Gi1/KB-752 by using AMoRe (35). Model
building was performed in O and Coot (36, 37), with refinement
conducted by using real-space refinement protocols in Coot as
well as a combination of rigid body, simulated annealing, energy
minimization, and b-factor protocols in CNS (38). All structural
images were made with PyMol (DeLano Scientific, South San
Francisco, CA) unless otherwise indicated.
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